Clinigen Group PLC 23.3% potential upside indicated by RBC Capital Markets

Clinigen Group PLC with ticker (LON:CLIN) now has a potential upside of 23.3% according to RBC Capital Markets.



RBC Capital Markets set a target price of 860 GBX for the company, which when compared to the Clinigen Group PLC share price of 660 GBX at opening today (27/10/2021) indicates a potential upside of 23.3%. Trading has ranged between 560 (52 week low) and 892 (52 week high) with an average of 911,198 shares exchanging hands daily. The market capitalisation at the time of writing is £858,559,958.

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.